Evenity safer than Tymlos / Forteo for Cardio Vascular Risk?

Posted by Michael Lavacot @michaellavacot, Apr 14 10:05am

Hey Everyone,

I know this is a huge topic on the site so I wanted to share a new study that was discussed at the 2024 World Congress of Osteoporosis. The study came to the conclusion "In a diverse real-world setting, prescription of romosozumab for osteoporosis is associated with less adverse CV events when compared to PTH analog therapy". You can find it here https://pubmed.ncbi.nlm.nih.gov/38482603/

Mike

Interested in more discussions like this? Go to the Osteoporosis & Bone Health Support Group.

windyshores | @windyshores | May 16 10:04pm

The FRAME study showed no difference between Evenity and placebo in cardiovascular risk. The ARCH study showed a small but statistically significant difference with alendronate.

I first read an article speculating this was due to a possible protective effect from alendronate. However, the last time I read a study on this, it said that after careful evaluation of all possible factors, they felt the difference was due to random chance.

I have other concerns about Evenity since sclerostin is found throughout the body. but people seem to do fine on it for the most part. I have read that it can affect bone marrow production of B cells, possibly- which means the effect on acquired immunity mentioned in McCormick's book.